Nuwiq (Vihuma) Market Report 2026

Nuwiq (Vihuma) Market Overview

• The Nuwiq (Vihuma) market growth in the historic period has been driven by increasing diagnosis of hemophilia a, limitations of plasma-derived therapies • Market expansion is supported by increasing demand for personalized dosing regimens, rising adoption of long-term prophylaxis • Growth Driver: Rising Prevalence Of Hemophilia A To Drive Growth In The Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Nuwiq (Vihuma) Market?

Nuwiq (Vihuma) refers to a recombinant human coagulation factor VIII therapy developed for the treatment and prevention of bleeding episodes in patients with hemophilia A. It is designed to replace the missing or deficient factor VIII, thereby supporting normal blood clotting. The main types of indications for nuwiq (vihuma) include on-demand treatment, prophylaxis, and perioperative management. On-demand treatment involves administering medication to control or stop bleeding episodes as they occur in patients with hemophilia. It is distributed through direct sales, pharmacies, and online pharmacies and is used by hospitals, home care, and specialized clinics.

What Is The Nuwiq (Vihuma) Market Growth Forecast?

The growth in the forecast period can be attributed to increasing demand for personalized dosing regimens, rising adoption of long-term prophylaxis, expansion of recombinant therapy pipelines, growing investments in rare blood disorder research, increasing home infusion adoption. Major trends in the forecast period include increasing adoption of recombinant coagulation therapies, rising preference for human cell line-derived factor viii, growing focus on prophylactic hemophilia management, expansion of home-based treatment models, enhanced emphasis on treatment safety and purity.

What Are The Drivers Of The Nuwiq (Vihuma) Market?

The rising prevalence of hemophilia A is expected to drive the growth of the nuwiq (vihuma) market going forward. Hemophilia A is a genetic bleeding disorder caused by a deficiency or dysfunction of clotting factor VIII, leading to prolonged bleeding. The prevalence of hemophilia A is rising due to improved diagnosis, increased awareness, and better survival rates among patients. Nuwiq (Vihuma) helps hemophilia A by providing a recombinant form of factor VIII that replaces the deficient or missing clotting protein, enabling effective blood clotting and preventing or controlling bleeding episodes. For instance, in November 2024, according to the National Institutes of Health (NIH), a U.S.-based government premier medical research agency, in the UK, between April 2022 and March 2023, a total of 6,662 males were recorded as having haemophilia A. Therefore, the rising global prevalence of hemophilia A is driving the growth of nuwiq (vihuma) industry. The increasing healthcare spending is expected to propel the growth of the nuwiq (vihuma) market going forward. Healthcare expenditure refers to the total spending on medical services, treatments, hospital care, pharmaceuticals, and other health-related services. Increasing healthcare expenditure is driven by factors such as an aging population, the rise of chronic diseases, and higher demand for healthcare services. Healthcare expenditure is beneficial for nuwiq (vihuma) by providing funding for the development, accessibility, and distribution of advanced hemophilia treatments, enabling broader patient access and supporting the integration of personalized therapies into treatment protocols. For instance, in May 2024, according to a report published by the Office for National Statistics, a UK-based government department, total healthcare expenditure increased by 5.6% in nominal terms between 2022 and 2023, compared with growth of 0.9% in 2022. Therefore, the increasing healthcare spending is driving the growth of the nuwiq (vihuma) industry. The rising focus on personalized medicine is expected to propel the growth of the nuwiq (vihuma) market going forward. Personalized medicines are medical interventions tailored to an individual's specific genetic, environmental, and lifestyle factors to optimize effectiveness and minimize side effects. The demand for personalized medicine is rising due to advancements in genetic research, increased awareness of individualized healthcare, and the growing recognition that tailored therapies offer improved efficacy and fewer side effects compared to traditional one-size-fits-all approaches. Nuwiq (Vihuma) helps personalized medicine by offering a tailored recombinant factor VIII therapy with individualized dosing and treatment plans, optimizing efficacy and minimizing risks for patients with hemophilia A. For instance, in February 2024, Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, a significant increase from the six approved in 2022. Therefore, the rising focus on personalized medicine is expected to drive the growth of the nuwiq (vihuma) market.

Key Players In The Global Nuwiq (Vihuma) Market

Major companies operating in the nuwiq (vihuma) market are Octapharma AG

What Defines the Nuwiq (Vihuma) Market?

The nuwiq (vihuma) market consists of sales of hemophilia treatment kits, coagulation testing kits and prothrombin complex concentrates. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Nuwiq (Vihuma) Market Report 2026?

The nuwiq (vihuma) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the nuwiq (vihuma) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.